{"id":251668,"date":"2021-05-15T00:00:00","date_gmt":"2021-05-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0043-biopharma-chronic-heart-failure-epidemiology-asia\/"},"modified":"2026-03-31T10:43:15","modified_gmt":"2026-03-31T10:43:15","slug":"epidcv0043-biopharma-chronic-heart-failure-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0043-biopharma-chronic-heart-failure-epidemiology-asia-pacific\/","title":{"rendered":"Chronic Heart Failure &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of chronic heart failure (<abbr title=\"chronic heart failure\">CHF<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of <abbr title=\"chronic heart failure\">CHF<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this content.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"chronic heart failure\">CHF<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"chronic heart failure\">CHF<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"chronic heart failure\">CHF<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"chronic heart failure\">CHF<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid atrial fibrillation (<abbr title=\"atrial fibrillation\">AF<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid chronic obstructive pulmonary disease (<abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid diabetes.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid hypertension.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid coronary heart disease (<abbr title=\"coronary heart disease\">CHD<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid dyslipidemia.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by history of myocardial infarction (<abbr title=\"myocardial infarction\">MI<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by history of stroke.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid obesity.<\/li>\n<li>Diagnosed prevalent <abbr title=\"chronic heart failure\">CHF<\/abbr> cases by New York Heart Association (<abbr title=\"New York Heart Association\">NYHA<\/abbr>) functional classification status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> characterized by reduced ejection fraction (<abbr title=\"ejection fraction\">EF<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr> characterized by preserved or mid-range <abbr title=\"ejection fraction\">EF<\/abbr>.<\/li>\n<li>\u2026 and more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251668","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-chronic-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251668\/revisions"}],"predecessor-version":[{"id":284115,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251668\/revisions\/284115"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}